Treatment with the cardiac myosin inhibitor significantly improved exercise capacity in patients with obstructive hypertrophic cardiomyopathy (HCM), an inherited disorder in which the heart muscle becomes thickened and can obstruct blood flow. It is one of the most common reasons for sudden cardiac death in people who are younger than 35.
The results of the 300-patient SEQUOIA-HCM study suggest Cytokinetics is on track to bring aficamten to market as a rival to Bristol-Myers Squibb’s Camzyos (mavacamten), which is currently the only FDA-approved treatment for HCM and has been tipped as a future blockbuster.
